ASH

December 13, 2021

63rd American Society of Hematology (ASH) Annual Meeting u0026 Exposition, December 11 – 14, 2021

Year

2021

Target

PIM/FLT3

Assets in this page

Download assets

  • pdf file

    "CLI120-001 Phase Ib Study of RVU120 (SEL120) in Patients with AML and High-Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation"

    Download
  • pdf file

    "RVU120 – a CDK8/19 Inhibitor for the Treatment of AML and HR-MDS Can Induce Erythroid Differentiation"

    Download
  • pdf file

    "Inhibition of Cyclin Dependent Kinase 8 (CDK8): A Novel Approach to Target the Leukemia Initiating Cells (LICs) in T-Cell Acute Lymphoblastic Leukemia (T-ALL)"

    Download
  • pdf file

    "Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML"

    Download
  • pdf file

    "SEL24(MEN1703) Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial"

    Download